MMBR Try MCB online
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Montero, M.
Right arrow Articles by Scott, J. K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montero, M.
Right arrow Articles by Scott, J. K.
Microbiology and Molecular Biology Reviews, March 2008, p. 54-84, Vol. 72, No. 1
1092-2172/08/$08.00+0     doi:10.1128/MMBR.00020-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design

Marinieve Montero,1,{dagger} Nienke E. van Houten,1,2,{dagger}* Xin Wang,1,{ddagger} and Jamie K. Scott1,2*

Department of Molecular Biology and Biochemistry,1 Faculty of Health Sciences, Simon Fraser University, 8888 University Drive, Burnaby V5A 1S6, British Columbia, Canada2

Summary: Enormous efforts have been made to produce a protective vaccine against human immunodeficiency virus type 1; there has been little success. However, the identification of broadly neutralizing antibodies against epitopes on the highly conserved membrane-proximal external region (MPER) of the gp41 envelope protein has delineated this region as an attractive vaccine target. Furthermore, emerging structural information on the MPER has provided vaccine designers with new insights for building relevant immunogens. This review describes the current state of the field regarding (i) the structure and function of the gp41 MPER; (ii) the structure and binding mechanisms of the broadly neutralizing antibodies 2F5, 4E10, and Z13; and (iii) the development of an MPER-targeting vaccine. In addition, emerging approaches to vaccine design are presented.


* Corresponding author. Mailing address: Department of Molecular Biology and Chemistry and Faculty of Health Sciences, Simon Fraser University, 8888 University Drive, Burnaby V5A 1S6, British Columbia, Canada. Phone: (778) 782-5656. Fax: (778) 782-5583. E-mail for Nienke E. van Houten: nvanhout{at}sfu.ca. E-mail for Jamie K. Scott: jkscott{at}sfu.ca

{dagger} M.M. and N.E.V.H. contributed equally.

{ddagger} Present address: Division of Infectious Diseases and Hospital Ep- idemiology, University Hospital Zurich, Zurich, Switzerland.


Microbiology and Molecular Biology Reviews, March 2008, p. 54-84, Vol. 72, No. 1
1092-2172/08/$08.00+0     doi:10.1128/MMBR.00020-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Appl. Environ. Microbiol. Infect. Immun. Eukaryot. Cell
Mol. Cell. Biol. J. Virol. J. Bacteriol.
ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.